Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC Jun 13, 2017 04:30PM
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2017 May 15, 2017 08:00AM
OncoGenex to Report First Quarter 2017 Financial Results on May 15, 2017 May 9, 2017 09:00AM
Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT") Mar 8, 2017 09:00AM
Achieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the National Institutes of Health to Advance the Development of Cytisine for Smoking Cessation Mar 1, 2017 09:00AM


Feb 23, 2017 09:00AM OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016
Feb 21, 2017 09:00AM OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
Feb 16, 2017 04:01PM OncoGenex to Report Year End 2016 Financial Results on Feb. 23, 2017
Jan 5, 2017 04:31PM OncoGenex Pharma (OGXI) to Merge with Achieve Life Science
Jan 5, 2017 04:30PM OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
Nov 10, 2016 04:01PM OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2016
Nov 3, 2016 04:01PM OncoGenex to Report Third Quarter 2016 Financial Results on Nov. 10, 2016
Oct 25, 2016 05:02PM OncoGenex Pharma (OGXI) Announces Strong Survival Data from Apatorsen Phase 2 in MBC
Oct 25, 2016 05:00PM OncoGenex Announces Positive Survival Results from Apatorsen Phase 2 Borealis-2™ Trial in Metastatic Bladder Cancer
Oct 13, 2016 07:31AM OncoGenex Pharma (OGXI) Announces Custirsen Phase 3 Missed Primary Endpoint in NSCLC
Oct 13, 2016 07:30AM OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer
Aug 16, 2016 07:01AM OncoGenex Pharma (OGXI) Announces Custirsen Phase 3 Missed Primary Endpoint in Metastatic CRPC
Aug 16, 2016 07:00AM OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
Aug 4, 2016 04:01PM OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016
Jul 21, 2016 04:01PM OncoGenex to Report Second Quarter 2016 Financial Results on August 4, 2016
May 12, 2016 04:01PM OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016
Apr 28, 2016 04:01PM OncoGenex to Report First Quarter 2016 Financial Results on May 12, 2016
Apr 5, 2016 04:02PM OncoGenex Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
Mar 9, 2016 04:01PM OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2015
Feb 24, 2016 04:01PM OncoGenex to Report Fourth Quarter and Year End 2015 Financial Results on March 9, 2016
Feb 4, 2016 04:49PM OncoGenex Pharma (OGXI) to Reduce Workforce by 27%
Feb 4, 2016 04:01PM OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities
Jan 21, 2016 09:28AM Pre-Open Stock Movers 01/21: (ZFGN) (XLNX) (FEYE) Higher; (OGXI) (ALKS) (SLM) Lower (more...)
Jan 20, 2016 04:02PM OncoGenex Pharma (OGXI) Announces Phase 2 Spruce Did Not Reach Statistical Significance
Jan 20, 2016 04:01PM OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer
Dec 9, 2015 07:02AM OncoGenex Pharma (OGXI) Announces IDSMB Recommendation to Continue Phase 2 Borealis-2 as Planned
Dec 9, 2015 07:00AM OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis
Dec 1, 2015 04:01PM OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses
Nov 12, 2015 04:05PM OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2015
Nov 5, 2015 04:15PM OncoGenex Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference
Oct 29, 2015 04:15PM OncoGenex to Report Third Quarter 2015 Financial Results on November 12, 2015
Oct 8, 2015 07:00AM OncoGenex Announces EMA Support for Phase 3 AFFINITY Trial Protocol Amendment
Sep 30, 2015 07:00AM OncoGenex Announces Completion of Patient Enrollment in Borealis-2™ Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer
Sep 28, 2015 01:00AM OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Surviva
Sep 23, 2015 07:00AM OncoGenex Announces Phase 2 Rainier Results in Previously Untreated Metastatic Pancreatic Cancer
Aug 13, 2015 04:00PM OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2015
Jul 30, 2015 04:00PM OncoGenex to Report Second Quarter 2015 Financial Results on August 13, 2015
Jul 13, 2015 07:00AM OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis
Jun 10, 2015 07:00AM FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment
Jun 1, 2015 10:45AM OncoGenex Announces Data from Borealis-1™ Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer
May 30, 2015 02:15PM OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis
May 20, 2015 04:00PM OncoGenex Announces Data to be Presented at ASCO 2015 Annual Meeting
May 14, 2015 04:01PM OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2015
May 4, 2015 04:01PM OncoGenex to Report First Quarter 2015 Financial Results on May 14, 2015
Apr 30, 2015 07:00AM OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
Apr 27, 2015 06:30AM OncoGenex Regains Rights to Custirsen from Teva
Apr 9, 2015 06:30AM OncoGenex Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference
Mar 26, 2015 04:01PM OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014
Mar 23, 2015 06:30AM OncoGenex to Report Financial Results for Fourth Quarter and Year End 2014 on March 26, 2015